Insulin resistance, adipocyte biology, and thiazolidinediones: A review

Metabolic Syndrome and Related Disorders

Volumn 5, Issue 2, 2007, Pages 103-115

  Tarcin, Ozlem ^a,c   Bajaj, Mandeep ^b   Akalin, Sema ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ANTIRETROVIRUS AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADIPOCYTE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYTOLOGY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FOOT EDEMA; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER FAILURE; LIVER TOXICITY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

EID: 34250726566     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2007.0001     Document Type: Review

References (121)

1. Kahn, B.B. and Flier, J.S. Obesity and insulin resistance. J Clin Invest 2000;106:473-481.
2. Danforth, E. Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 2000;26:13.
3. Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R.E. and Tataranni, P.A. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
4. Thiebaud, D., DeFronzo, R.A., Jacot, E., Golay, A., Acheson, K., Maeder, E., Jequier, E. and Felber, J.P. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism 1982;31:1128-1136.
5. Boden, G., Jadali, F., White, J., Liang, Y., Mozzoli, M., Chen, X., Coleman, E. and Smith, C. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 1991;88:960-966.
6. Chen, X., Iqbal, N. and Boden, G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 1999;103:365-372.
7. Ferrannini, E., Barrett, E.J., Bevilacqua, S. and DeFronzo, R.A. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-1747.
8. Kashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Berria, R., Pratipanawatr, W., Bajaj, M., Mandarino, L., DeFronzo, R. and Cusi, K. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-2474.
9. Carpentier, A., Mittelman, S.D., Lamarche, B., Bergman, R.N., Giacca, A. and Lewis, G.F. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 1999;276:E1055-1066.
10. Pittas, A.G., Joseph, N.A. and Greenberg, A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004;89:447-452.
11. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., Kuriyama, H., Nishida, M., Yamashita, S., Okubo, K., Matsubara, K., Muraguchi, M., Ohmoto, Y., Funahashi, T. and Matsuzawa, Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:7983.
12. Matsubara, M., Maruoka, S. and Katayose, S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002;87:2764-2769.
13. Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., Nishida, M., Kihara, S., Sakai, N., Nakajima, T., Hasegawa, K., Muraguchi, M., Ohmoto, Y., Nakamura, T., Yamashita, S., Hanafusa, T. and Matsuzawa, Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599.
14. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C., Reitman, M.L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P. and Kadowaki, T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
15. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., Eto, K., Akanuma, Y., Froguel, P., Foufelle, F., Ferre, P., Carling, D., Kimura, S., Nagai, R., Kahn, B.B. and Kadowaki, T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
16. Ouchi, N., Kihara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., Hotta, K., Nishida, M., Takahashi, M., Nakamura, T., Yamashita, S., Funahashi, T. and Matsuzawa, Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476.
17. Arita, Y., Kihara, S., Ouchi, N., Maeda, K., Kuriyama, H., Okamoto, Y., Kumada, M., Hotta, K., Nishida, M., Takahashi, M., Nakamura, T., Shimomura, I., Muraguchi, M., Ohmoto, Y., Funahashi, T. and Matsuzawa, Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002;105:2893-2898.
18. Yu, J.G., Javorschi, S., Hevener, A.L., Kruszynska, Y.T., Norman, R.A., Sinha, M. and Olefsky, J.M. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-2974.
19. Hotamisligil, G.S., Shargill, N.S. and Spiegelman, B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
20. Moller, D.E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000;11:212-217.
21. Hauner, H., Petruschke, T., Russ, M., Rohrig, K. and Eckel, J. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995;38:764-771.
22. Porter, M.H., Cutchins, A., Fine, J.B., Bai, Y. and DiGirolamo, M. Effects of TNF-alpha on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J Lab Clin Med 2002;139:140-146.
23. Pickup, J.C., Mattock, M.B., Chusney, GD. and Burt, D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292.
24. Katsuki, A., Sumida, Y., Murashima, S., Murata, K., Takarada, Y., Ito, K., Fujii, M., Tsuchihashi, K., Goto, H., Nakatani, K. and Yano, Y. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:859-862.
25. Kappes, A. and Loffler, G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000;32:548-554.
26. Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I. and Matsuzawa, Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-2099.
27. Grunfeld, C. and Feingold, K.R. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991;3:143-158.
28. Ebihara, K., Ogawa, Y., Masuzaki, H., Shintani, M., Miyanaga, F., Aizawa-Abe, M., Hayashi, T., Hosoda, K., Inoue, G., Yoshimasa, Y., Gavrilova, O., Reitman, M.L. and Nakao, K. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 2001;50:1440-1448.
29. Colombo, C., Cutson, J.J., Yamauchi, T., Vinson, C., Kadowaki, T., Gavrilova, O. and Reitman, M.L. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 2002;51:2727-2733.
30. Unger, R.H., Zhou, Y.T. and Orci, L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A 1999;96:2327-2332.
31. Minokoshi, Y., Kim, Y.B., Peroni, O.D., Fryer, L.G., Muller, C., Carling, D. and Kahn, BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.
32. Stephens, J.M. and Pekala, P.H. Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J Biol Chem 1992;267:13580-13584.
33. Banks, R.E., Forbes, M.A., Storr, M., Higginson, J., Thompson, D., Raynes, J., Illingworth, J.M., Perren, T.J., Selby, P.J. and Whicher, J.T. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995;102:217-223.
34. Grunfeld, C., Zhao, C., Fuller, J., Pollack, A., Moser, A., Friedman, J. and Feingold, K.R. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996;97:2152-2157.
35. Bullo, M., Garcia-Lorda, P., Megias, I. and Salas-Salvado, J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003;11:525-531.
36. Sonnenberg, G.E., Krakower, G.R. and Kissebah, A.H. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180-186.
37. Karin, M. and Delhase, M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000;12:85-98.
38. Stumvoll, M., Goldstein, B.J. and van Haeften, T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-1346.
39. Libby, P., Ridker, P.M. and Maseri, A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
40. Weyer, C., Yudkin, J.S., Stehouwer, C.D., Schalkwijk, C.G., Pratley, R.E. and Tataranni, P.A. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002; 161:233-242.
41. Ouchi, N., Kihara, S., Arita, Y., Okamoto, Y., Maeda, K., Kuriyama, H., Hotta, K., Nishida, M., Takahashi, M., Muraguchi, M., Ohmoto, Y., Nakamura, T., Yamashita, S., Funahashi, T. and Matsuzawa, Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-1301.
42. Willson, T.M., Lambert, M.H. and Kliewer, S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001;70:341-367.
43. Dubois, M., Pattou, F., Kerr-Conte, J., Gmyr, V., Vandewalle, B., Desreumaux, P., Auwerx, J., Schoonjans, K. and Lefebvre, J . Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000;43:1165-1169.
44. Hallakou, S., Doare, L., Foufelle, F., Kergoat, M., Guerre-Millo, M., Berthault, M.F., Dugail, I., Morin, J., Auwerx, J. and Ferre, P. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997;46:1393-1399.
45. Gurnell, M., Wentworth, J.M., Agostini, M., Adams, M., Collingwood, T.N., Provenzano, C., Browne, P.O., Rajanayagam, O., Burris, T.P., Schwabe, J.W., Lazar, M.A. and Chatterjee, V.K. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem 2000;275:5754-5759.
46. Rosen, E.D. and Spiegelman, B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-37734.
47. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.M., Heyman, R.A., Briggs, M., Deeb, S., Staels, B. and Auwerx, J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J 1996;15:5336-5348.
48. Tontonoz, P., Hu, E., Devine, J., Beale, E.G. and Spiegelman, B.M. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1995;15:351-357.
49. Olswang, Y., Cohen, H., Papo, O., Cassuto, H., Croniger, C.M., Hakimi, P., Tilghman, S.M., Hanson, R.W. and Reshef, L. A mutation in the peroxisome proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proc Natl Acad Sci USA 2002;99:625-630.
50. Walczak, R. and Tontonoz, P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 2002;43:177-186.
51. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M. and Kliewer, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953-12956.
52. Okuno, A., Tamemoto, H., Tobe, K., Ueki, K., Mori, Y., Iwamoto, K., Umesono, K., Akanuma, Y., Fujiwara, T., Horikoshi, H., Yazaki, Y. and Kadowaki, T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101:1354-1361.
53. Miyazaki, Y., Glass, L., Triplitt, C., Matsuda, M., Cusi, K., Mahankali, A., Mahankali, S., Mandarino, L.J. and DeFronzo, R.A. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001;44:2210-2219.
54. Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L.J. and DeFronzo, R.A. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-719.
55. Miyazaki, Y., Mahankali, A. Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L.J. and DeFronzo, R.A. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791.
56. Mayerson, A.B., Hundal, R.S., Dufour, S., Lebon, V., Befroy, D., Cline, G.W., Enocksson, S., Inzucchi, S.E., Shulman, G.I. and Petersen, K.F. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802.
57. Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L.J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y. and DeFronzo, R.A. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003;52:1364-1370.
58. Silverman, J.F., Pories, W.J. and Caro, J.F. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 1989;24:275-302.
59. Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M. and Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-1193.
60. Bajaj, M., Suraamornkul, S., Piper, P., Hardies, L.J., Glass, L., Cersosimo, E., Pratipanawatr, T., Miyazaki, Y. and DeFronzo, R.A. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200-206.
61. Bajaj, M., Suraamornkul, S., Romanelli, A., Cline, G.W., Mandarino, L.J., Shulman, G.I. and DeFronzo, R.A. Effect of a sustained reduction in plasma free fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes 2005;54:3148-3153.
62. Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S. and Lazar, M.A. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
63. Marx, N., Froehlich, J., Siam, L., Ittner, J., Wierse, G., Schmidt, A., Scharnagl, H., Hombach, V. and Koenig, W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:283-288.
64. Haffner, S.M., Greenberg, A.S., Weston, W.M., Chen, H., Williams, K. and Freed, M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106: 679-84.
65. Harte, A.L., McTernan, P.G., McTernan, C.L., Smith, S.A., Barnett, A.H. and Kumar, S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 2003;5:302-310.
66. de Souza, C.J., Eckhardt, M., Gagen, K., Dong, M., Chen, W., Laurent, D. and Burkey, B.F. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001;50:1863-1871.
67. Phillips, S.A., Ciaraldi, T.P., Kong, A.P., Bandukwala, R., Aroda, V. Carter, L., Baxi, S., Mudaliar, S.R. and Henry, R.R. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003;52:667-674.
68. Higa, M., Zhou, Y.T., Ravazzola, M., Baetens, D., Orci, L.and Unger, R.H. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 1999;96:11513-11518.
69. Qvigstad, E., Mostad, I.L., Bjerve, K.S. and Grill, V.E. Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. Am J Physiol Endocrinol Metab 2003;284:E129-37.
70. Buchanan, T.A., Xiang, A.H., Peters, R.K., Kjos, S.L., Marroquin, A., Goico, J., Ochoa, C. Tan, S., Berkowitz, K., Hodis, H.N. and Azen, S.P. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-2803.
71. Xiang, A.H., Peters, R.K., Kjos, S.L., Goico J, Marroquin, A., Ochoa, C. Tan, S., and Buchanan T. Continued protection from diabetes during treatment of the TRIPOD cohort with pioglitazone. Diabetes 2003;52(suppl 1):A75.
72. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105.
73. Tuomilehto, J., Lindstrom, J., Eriksson, J.G., Valle, T.T., Hamalainen, H., Ilanne-Parikka, P., Keinanen-Kiukaanniemi, S., Laakso, M., Louheranta, A. Rastas, M., Salminen, V. and Uusitupa, M.,; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
74. Kahn, S.E., Haffner, S.M., Heise, M.A., Herman, W.H., Holman, R.R., Jones, N.P., Kravitz, B.G., Lachin, J.M., O'Neill, M.C., Zinman, B. and Viberti, G.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
75. Nathan, D.M. Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 2006;355:2477-2480.
76. Gitlin, N., Julie, N.L., Spurr, C.L., Lim, K.N. and Juarbe, H.M. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129:36-38.
77. Bajaj, M. and DeFronzo, R.A., Combination therapy in type 2 diabetes, ed. E.F. RA DeFronzo, H Keen, P Zimmet, International Textbook of Diabetes Mellitus, Third ed., Chichester, USA: John Wiley & Sons Ltd., 2004.
78. Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J.W., Mathisen, A.L. and Schneider, R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-1611.
79. Phillips, L.S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E.B. and Salzman A.; Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-315.
80. Pavo, I., Jermendy, G., Varkonyi, T.T., Kerenyi, Z., Gyimesi, A., Shoustov, S., Shestakova, M. Herz, M., Johns, D., Schluchter, B.J., Festa, A. and Tan, M.H. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:1637-1645.
81. Derosa, G., D'Angelo, A., Ragonesi, P.D., Ciccarelli, L. Piccinni, M.N., Pricolo, F., Salvadeo, S.A., Montagna, L., Gravina, A., Ferrari, I., Paniga, S. and Cicero, A.F. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-383.
82. Derosa, G., Cicero, A.F., D'Angelo, A., Gaddi, A., Ciccarelli, L., Piccinni, M.N., Salvadeo, S.A., Pricolo, F., Ferrari, I., Gravina, A. and Ragonesi, P.D. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein(a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006;28:679-688.
83. Raskin, P., Rendell, M., Riddle, M.C., Dole, J.F., Freed, M.I. and Rosenstock, J.; Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-1232.
84. Strowig, S.M. and Raskin, P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab 2005;7:633-641.
85. Goldberg, R.B., Kendall, D.M., Deeg, M.A., Buse, J.B., Zagar, A.J., Pinaire, J.A., Tan, M.H., Khan, M.A., Perez, A.T. and Jacober, S.J.; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554.
86. Derosa, G., D'Angelo, A., Ragonesi, P.D., Ciccarelli, L., Piccinni, M.N., Pricolo, F., Salvadeo, S.A., Montagna, L., Gravina, A., Ferrari, I., Paniga, S. and Cicero,A.F. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-383.
87. Shargorodsky, M., Wainstein, J., Gavish, D., Leibovitz, E., Matas, Z. and Zimlichman, R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003;16:617-622.
88. Gerber, P., Lubben, G., Heusler, S.and Dodo, A. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin 2003;19:532-539.
89. Kato, K., Satoh, H., Endo, Y., Yamada, D., Midorikawa, S., Sato, W., Mizuno, K., Fujita, T., Tsukamoto, K. and Watanabe, T. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 1999;258:431-435.
90. Watanabe, Y., Sunayama, S. Shimada, K., Sawano, M., Hoshi, S., Iwama, Y., Mokuno, H., Daida, H. and Yamaguchi, H. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000;7:159-163.
91. Natali, A., Baldeweg, S., Toschi, E., Barbara, D., Capaldo, B., Yudkin, J. and Ferrannini, E. Rosiglitazone directly improves endothelial function in type 2 diabetic patients. Diabetes 2002;51(suppl 2):A142.
92. Franks, S., Gilling-Smith, C., Watson, H. and Willis, D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999;28:361-378.
93. Reitman, M.L., Arioglu, E., Gavrilova, O. and Taylor, S.I. Lipoatrophy revisited. Trends Endocrinol Metab 2000;11:410-416.
94. Clark, J.M., Brancati, F.L. and Diehl, A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967.
95. Vozarova, B., Stefan, N., Lindsay, R.S., Saremi, A., Pratley, R.E., Bogardus, C. and Tataranni, P.A. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:1889-1895.
96. Seppala-Lindroos, A., Vehkavaara, S., Hakkinen, A.M., Goto, T., Westerbacka, J., Sovijarvi, A. Halavaara, J.and Yki-Jarvinen, H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
97. Ryysy, L., Hakkinen, A.M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J. and Yki-Jarvinen, H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-758.
98. Carey, D.G., Cowin, G.J., Galloway, G.J., Jones, N.P., Richards, J.C., Biswas, N. and Doddrell, D.M. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res 2002;10:1008-1015.
99. Tiikkainen, M., Hakkinen, A.M., Korsheninnikova, E., Nyman, T., Makimattila, S. and Yki-Jarvinen, H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176.
100. Sutinen, J., Hakkinen, A.M., Westerbacka, J., Seppala-Lindroos, A., Vehkavaara, S., Halavaara, J., Jarvinen, A., Ristola, M. and Yki-Jarvinen, H. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 2003;8:199-207.
101. Neuschwander-Tetri, B.A., Brunt, E.M., Wehmeier, K.R., Oliver, D. and Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-1017.
102. Promrat, K., Lutchman, G., Uwaifo, G.I., Freedman, R.J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., Liang, T.J., Yanovski, J.A., Kleiner, D.E. and Hoofnagle, J.H. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-196.
103. Solomon, C.G. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 1999;28:247-263.
104. Azziz, R., Ehrmann, D., Legro, R.S., Whitcomb, R.W., Hanley, R., Fereshetian, A.G., O'Keefe, M. and Ghazzi, M.N.; PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-1632.
105. Ghazeeri, G., Kutteh, W.H., Bryer-Ash, M., Haas, D. and Ke, R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79:562-566.
106. Yilmaz, M., Biri, A., Karakoc, A., Toruner, F., Bingol, B., Cakir, N., Tiras, B., Ayvaz, G. and Arslan, M. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 2005;28:1003-1008.
107. Yilmaz, M., Karakoc, A., Toruner, F.B., Cakir, N., Tiras, B., Ayvaz, G. and Arslan, M. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 2005;21:154-160.
108. Yki-Jarvinen, H., Sutinen, J., Silveira, A., Korsheninnikova, E., Fisher, R.M., Kannisto, K., Ehrenborg, E., Eriksson, P. and Hamsten, A. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 2003;23:688-694.
109. Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., Skene, A.M., Tan, M.H., Lefebvre, P.J., Murray, G.D., Standl, E., Wilcox, R.G., Wilhelmsen, L., Betteridge, J., Birkeland, K., Golay, A., Heine, R.J., Koranyi, L., Laakso, M., Mokan, M., Norkus, A., Pirags, V., Podar, T., Scheen, A., Scherbaum, W. Schernthaner, G., Schmitz, O., Skrha, J., Smith, U. and Taton, J.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289.
110. Mazzone, T., Meyer, P.M., Feinstein,S.B., Davidson, M.H., Kondos, G.T., D'Agostino, R.B. Sr, Perez, A., Provost, J.C. and Haffner, S.M. Effect of pioglitazone compared with glimepiride on carotid intime media thickness in type 2 diabetes: A randomized trial. Jama 2006;296:2572-2781.
111. Lebovitz, H.E., Kreider, M. and Freed, M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002;25:815-821.
112. Baba, S. Pioglitazone: a review of Japanese clinical studies. Curr Med Res Opin 2001;17:166-189.
113. Yki-Jarvinen, H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
114. Avandia(rosiglitazone maleate) [package insert]. Philedelphia, GlaxoSmithKline, 2000.
115. Saad, M.F., Greco, S., Osei, K., Lewin, A.J., Edwards, C., Nunez, M. and Reinhardt, R.R.; Ragaglitazar Dose-Ranging Study Group. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12 week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 2004;27:1324-1329.
116. Spiegelman, B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514.
117. Nesto, R.W., Bell, D., Bonow, R.O., Fonseca, V., Grundy, S.M., Horton, E.S., Le Winter, M., Porte, D., Semenkovich, C.F., Smith, S., Young, L.H. and Kahn, R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-263.
118. Raskin, P., Rendell, M., Riddle, M.C., Dole, J.F., Freed, M.I. and Rosenstock, J.; Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-1232.
119. Ghazzi, M.N., Perez, J.E., Antonucci, T.K., Driscoll, J.H., Huang, S.M., Faja, B.W. and Whitcomb, R.W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997;46:433-439.
120. Ali, A.A., Weinstein, R.S., Stewart, S.A., Parfitt, A.M., Manolagas, S.C. and Jilka, R.L. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-1235.
121. Soroceanu, M.A., Miao, D., Bai, X.Y., Su, H., Goltzman, D. and Karaplis, A.C. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183:203-216.